SCPH scPharmaceuticals: Enterprise Value to Sales Volume

scPharma (SCPH) - corporate logo

The price-to-sales trajectory of scPharmaceuticals Inc. (SCPH) reflects asset dynamics where represents the latest metric reading. High barriers to entry are established by delivery device patents and the complexity of FDA certification. This advantage is strengthened by the commercial success of Furoscix, which reduces clinic costs. The business relies on wearable furosemide delivery systems, enabling heart failure patients to receive outpatient treatment.

scPharmaceuticals Inc. - SCPH EV/Sales Multiple (period 07/04/2022 - 11/19/2026)

SCPH (scPharmaceuticals): analytical breakdowns and indicator data

- market value and analyst target forecast:
- company stock capitalization data:
Fundamental company valuation:SCPH - scPharmaceuticals, Inc.
Product sample of scpharmaceuticals.com

The development of innovative drug delivery systems by scPharmaceuticals Inc. (SCPH) is reflected in the dynamics of the EV/Revenue multiple. This indicator compares market capitalization plus net debt against annual turnover, eliminating the influence of financing structure. This allows for an assessment of the business's real value regardless of the debt load. For an R&D-oriented company, such a metric reveals the true value of its intellectual potential. Investors should use this chart to filter out market noise when determining the asset's fair value.

Competitor analysis for scPharmaceuticals Inc.

HLN: Enterprise Value-to-Revenue Ratio|Kenvue Corp (KVUE) - Enterprise Value-to-Revenue Ratio|Verona Pharma PLC - Business Value to Revenue|Enterprise Value-to-Revenue Ratio Jyong Biotech Ltd|EV/Sales Multiple Ligand Corp|EV/Sales Multiple AMRX|Total Company Value-to-Revenue Ratio Perrigo Company plc|EV/Sales Multiple ALVO (Alvotech Biopharmaceuticals)|LQDA: Company Value to Revenue Ratio|Galapagos N.V. - EV/Sales Multiple|ANIP - EV/Sales Multiple|MNKD: EV/Sales Multiple|amphastar.com (AMPH) - EV/Sales Multiple|PCRX (Pacira Pharmaceuticals) - EV/Sales Multiple|Company Value to Revenue ARS Pharmaceuticals, Inc. (SPRY)|EV/Sales Multiple TBPH|AQST (Aquestive Therapeutics) - Business Value to Revenue|EV/Sales Multiple TECX (Tectonic Therapeutic, Inc.)|TNXP - Company Value to Revenue|China SXT Pharmaceuticals, Inc. - EV/Sales Multiple|EPRX - EV/Sales Multiple|BHST: EV/Sales Multiple|Enterprise Value-to-Revenue Multiple eXoZymes Inc (EXOZ)|ORMP (oramed.com) - EV/Sales Multiple|Company Value to Revenue Ratio ENTX (Entera Bio)|Enterprise Value-to-Revenue Ratio MindWalk (HYFT)|EV/Sales Multiple ABVC BioPharma, Inc. (ABVC)|Enterprise Value-to-Revenue Ratio Cumberland Corp CPIX|QNTM - Company Value to Revenue|FGEN - Enterprise Value-to-Revenue Ratio|TELO - EV/Sales Multiple|Rani Therapeutics Inc (RANI) - Enterprise Value-to-Revenue Ratio|Company Value to Revenue Ratio SNYR|Enterprise Value-to-Revenue Ratio Rallybio Corp|Enterprise Value-to-Revenue Ratio LEXX|EV/Sales Multiple PULM|PTHL: Enterprise Value to Sales Volume|EV/Sales Multiple APM (Aptorum Group Ltd)|LYRA - Company Value to Revenue|Impact BioMedical Inc - EV/Sales Multiple|Enterprise Value to Sales Volume TNFA|YCBD (cbdmd.com) - Company Value to Revenue|painreform.com - Business Value to Revenue|Company Value to Revenue CYTO|Enterprise Value-to-Revenue Ratio LIPO|Enterprise Value-to-Revenue Ratio optinose.com (OPTN)|PIRS (Pieris Pharma) - Business Value to Revenue|Enterprise Value-to-Revenue Ratio Procaps Group S.A. PROC|Total Company Value-to-Revenue Ratio petrospharma.com (PTPI)|QLI - Enterprise Value-to-Revenue Ratio|Business Value to Revenue SLRN (ACELYRIN)|TFF Pharmaceuticals, Inc (TFFP) - Enterprise Value-to-Revenue Ratio